Thomas Skripuletz

#MultipleSclerosis #SjögrenSyndrome #NeuroSjögren #CIDP #Neuropathy #PsychoNeuroImmunology #NeuroImmunOncology #PML #Cerebrospinal_Fluid

[JAMA Neurology @JAMANeuro]

Patients with detectable virus-specific T cells before checkpoint inhibitor therapy in #PML demonstrated better survival rates and functional recovery than those without. https://t.co/zSdJOnUAJ3

[JAMA Neurology @JAMANeuro]

Patients with detectable virus-specific T cells before checkpoint inhibitor therapy in #PML demonstrated better survival rates and functional recovery than those without. https://t.co/GhYHQkeZm5

[Thomas Skripuletz @NeuroSkripuletz]

JAMA Neurology | Our new paper on PML

Preexisting JC or BK virus specific T cells are associated with better response and survival under checkpoint inhibitors. An important step toward biomarker guided treatment decisions!

https://t.co/oTapemirJJ

[Thomas Skripuletz @NeuroSkripuletz]

https://t.co/fjgP9kJFG5

[JAMA Neurology @JAMANeuro]

Case series of DIAVIS T-cell therapy in progressive multifocal leukoencephalopathy provides first class IV evidence suggesting efficacy to reduce mortality and improve functional outcome. https://t.co/rjUOYdHwYj

[Therapeutic Advances in Neurological Disorders @TANeurolDisord]

🦠New case report: Combined allogeneic T-cell therapy for treating PML and EBV co-infection in #HIV patients demonstrates promising results with marked neurological improvement. Discover the details: https://t.co/S90FUlj67F

@NeuroSkripuletz @GunterHoglinger @MohnNora #PML #EBV https://t.co/825lTNhKes

[Johann Bauersachs @JBauersachsMD]

Jetzt‼️
➡️ 3. Amyloidose Forum des Amyloidosezentrums Niedersachsen
Im Alten Rathaus in Hannover

⁦@MHH_life⁩ ⁦@DocDerda⁩ ⁦@DavidDuncker⁩ ⁦@SamiraSoltaniMD⁩ ⁦@TRassafMD⁩ ⁦@HenrikeHillmann⁩

[Thomas Skripuletz @NeuroSkripuletz]

@gerritgrosse @Maria_M_Gabriel @ISHENliver @KarinWeissenb @alena_eh3 @b_maasoumy Great !

[Thomas Skripuletz @NeuroSkripuletz]

@MHH_life Congratulations!

[PRACTIS @PRACTIS_MHH]

Congratulations to our fellow @gerritgrosse for his vienna ligendi in "experimental neurology". #ClinicianScientist #MHH

[Thomas Skripuletz @NeuroSkripuletz]

We were delighted to have the opportunity, in collaboration with #Sven_Meuth, to comment on the current diagnostic criteria for #optic_neuritis with our data in #Lancet Neurology.

https://t.co/1tu8o83XQ1

[Thomas Skripuletz @NeuroSkripuletz]

We hope that with this review we can facilitate the selection of appropriate therapy in patients with #multiple_sclerosis and #comorbid #autoimmune diseases.

https://t.co/EkcPh4PBPw

[Nora Möhn @MohnNora]

#neurowoche2022 it was a pleasure!
Besides the contact to many great colleagues and new research ideas, the awarding of one of the poster prizes for our work on treatment of PML with virusspecific T cells was a true highlight! See you next year #DGN
@PRACTIS_MHH @NeuroSkripuletz

[Nora Möhn @MohnNora]

Proud to have such a great cooperation with my hematological colleagues and friends!!

https://t.co/ThoMP0iuhG

[Pharmaceuticals MDPI @Pharmaceut_MDPI]

Research by Dr. Viktoria Gudi proofed #CDPcholine could become a promising regenerative substance for patients with #MultipleSclerosis and should be tested in a clinical trial.

#Microglia #Astrocytes

📄Read this latest publication via:
https://t.co/lRehOu8eB0

[Susanne Fleig @fleig_s]

Long term B cell depletion associates with regeneration of kidney function (open access) https://t.co/CmChBpRubD #NephTwitter #rituximab

[PRACTIS @PRACTIS_MHH]

Congratulations to @PRACTIS_MHH supported @MohnNora on winning the 2021 DGLN poster award for her project
"Differentiation between viral and autoimmune CNS inflammation using the kynurenine signaling pathway".

https://t.co/B7FzVRzpqc

[Thomas Skripuletz @NeuroSkripuletz]

Eine tolle Aktion der #DMSG Niedersachsen zum Thema #Multiple #Sklerose. Viele interessante Beiträge, auch der #Neurologie der MHH. https://t.co/LVVgaPoRZZ

[Thomas Skripuletz @NeuroSkripuletz]

#Transplantation of #virus specific T cells from healthy donors represents a promising innovative therapy for #PML. Succesfull treatment at #Neurology Hannover Medical School.

https://t.co/OO4nLfAIOn

[Thomas Skripuletz @NeuroSkripuletz]

An overview of published cases shows that #immunosuppressive therapy in #MultipleSclerosis does not appear to be a substantial risk factor for severe #COVID19 course.

https://t.co/Eohb9dKcaM